Conduit Pharmaceuticals Inc.
CDT
$0.6201
-$0.16-20.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.91M | 10.60M | 8.71M | 6.91M | 5.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.29M | 13.94M | 8.95M | 7.13M | 5.69M |
| Operating Income | -16.29M | -13.94M | -8.95M | -7.13M | -5.69M |
| Income Before Tax | -17.80M | -15.15M | -6.07M | -2.79M | -908.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.80 | -15.15 | -6.07 | -2.79 | -0.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.80M | -15.15M | -6.07M | -2.79M | -908.00K |
| EBIT | -16.29M | -13.94M | -8.95M | -7.13M | -5.69M |
| EBITDA | -9.74M | -5.41M | -- | -- | -- |
| EPS Basic | -21.66 | -19.18 | -7.75 | -3.72 | -1.50 |
| Normalized Basic EPS | -13.51 | -11.42 | -4.85 | -2.33 | -0.94 |
| EPS Diluted | -21.85 | -23.36 | -15.29 | -11.26 | -9.04 |
| Normalized Diluted EPS | -13.51 | -11.42 | -4.88 | -2.32 | -0.92 |
| Average Basic Shares Outstanding | 3.47M | 3.08M | 2.86M | 2.77M | 2.68M |
| Average Diluted Shares Outstanding | 3.47M | 3.10M | 2.89M | 2.81M | 2.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |